Adaptive Biotechnologies Balance Sheet Health
Financial Health criteria checks 5/6
Adaptive Biotechnologies has a total shareholder equity of $223.6M and total debt of $132.7M, which brings its debt-to-equity ratio to 59.4%. Its total assets and total liabilities are $558.5M and $334.9M respectively.
Key information
59.4%
Debt to equity ratio
US$132.70m
Debt
| Interest coverage ratio | n/a |
| Cash | US$243.33m |
| Equity | US$223.57m |
| Total liabilities | US$334.93m |
| Total assets | US$558.51m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1HM's short term assets ($308.3M) exceed its short term liabilities ($87.6M).
Long Term Liabilities: 1HM's short term assets ($308.3M) exceed its long term liabilities ($247.3M).
Debt to Equity History and Analysis
Debt Level: 1HM has more cash than its total debt.
Reducing Debt: 1HM's debt to equity ratio has increased from 0% to 59.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1HM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 1HM has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 29.6% each year